Jennifer Kim
Stock Analyst at Cantor Fitzgerald
(1.64)
# 2,992
Out of 4,817 analysts
41
Total ratings
35%
Success rate
-4.04%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Jennifer Kim
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BLTE Belite Bio | Reiterates: Overweight | n/a | $54.30 | - | 4 | Mar 18, 2025 | |
| INSM Insmed | Reiterates: Overweight | n/a | $69.51 | - | 8 | Feb 20, 2025 | |
| FBIO Fortress Biotech | Reiterates: Overweight | n/a | $1.50 | - | 4 | Jun 20, 2024 | |
| EYPT EyePoint Pharmaceuticals | Reiterates: Overweight | n/a | $5.90 | - | 6 | Jun 20, 2024 | |
| ALLK Allakos | Reiterates: Neutral | n/a | $0.33 | - | 4 | Jun 20, 2024 | |
| PGEN Precigen | Reiterates: Overweight | n/a | $1.38 | - | 3 | May 15, 2024 | |
| OCGN Ocugen | Maintains: Overweight | $2.5 → $2 | $0.68 | +194.12% | 2 | Aug 31, 2023 | |
| CKPT Checkpoint Therapeutics | Maintains: Overweight | $19 → $14 | $4.04 | +246.96% | 4 | Aug 15, 2023 | |
| LPCN Lipocine | Reiterates: Overweight | $33 | $3.00 | +1,000.00% | 2 | Jul 27, 2023 | |
| PRQR ProQR Therapeutics | Maintains: Overweight | $5 → $4.5 | $1.32 | +240.91% | 2 | May 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $220 → $100 | $1.03 | +9,608.74% | 2 | May 17, 2022 |
Belite Bio
Mar 18, 2025
Reiterates: Overweight
Price Target: n/a
Current: $54.30
Upside: -
Insmed
Feb 20, 2025
Reiterates: Overweight
Price Target: n/a
Current: $69.51
Upside: -
Fortress Biotech
Jun 20, 2024
Reiterates: Overweight
Price Target: n/a
Current: $1.50
Upside: -
EyePoint Pharmaceuticals
Jun 20, 2024
Reiterates: Overweight
Price Target: n/a
Current: $5.90
Upside: -
Allakos
Jun 20, 2024
Reiterates: Neutral
Price Target: n/a
Current: $0.33
Upside: -
Precigen
May 15, 2024
Reiterates: Overweight
Price Target: n/a
Current: $1.38
Upside: -
Ocugen
Aug 31, 2023
Maintains: Overweight
Price Target: $2.5 → $2
Current: $0.68
Upside: +194.12%
Checkpoint Therapeutics
Aug 15, 2023
Maintains: Overweight
Price Target: $19 → $14
Current: $4.04
Upside: +246.96%
Lipocine
Jul 27, 2023
Reiterates: Overweight
Price Target: $33
Current: $3.00
Upside: +1,000.00%
ProQR Therapeutics
May 17, 2023
Maintains: Overweight
Price Target: $5 → $4.5
Current: $1.32
Upside: +240.91%
May 17, 2022
Maintains: Overweight
Price Target: $220 → $100
Current: $1.03
Upside: +9,608.74%